CIK 0001781174 · <br>Emerging growth company
Acrivon Therapeutics, Inc.
Sign in to watch- Ticker
- ACRV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 825125532
- Phone
- 617-207-8979
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $38,534
- in 8 filings
Net −$38,534. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blume-Jensen Peter −$34K President and CEO sold <1% of stake
- Miller Mary −$2K Chief Legal Officer sold 1% of stake
- Devroe Eric −$1K Chief Operating Officer sold <1% of stake
- Gamelin Erick −$804 Chief Development Officer sold <1% of stake
- Peterson Katharine −$203 Chief Accounting Officer sold <1% of stake
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-14 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −1,253 | $1.92 | $2K | 2,078,951 |
| 2026-05-14 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −490 | $1.92 | $941 | 313,637 |
| 2026-04-22 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award | +3,888,888 | $1.80 | $7.0M | 11,803,094 |
| 2026-04-17 | Miller Mary Chief Legal Officer | Shares withheld for taxes | −558 | $1.78 | $993 | 33,121 |
| 2026-03-01 | Peterson Katharine Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +31,900 | 31,900 | ||
| 2026-03-01 | Mirza Mansoor Raza Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +174,068 | 174,068 | ||
| 2026-03-01 | Miller Mary Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +129,760 | 129,760 | ||
| 2026-03-01 | Levy Adam D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +132,925 | 132,925 | ||
| 2026-03-01 | Gamelin Erick Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +94,946 | 94,946 | ||
| 2026-03-01 | Devroe Eric Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +186,728 | 186,728 | ||
| 2026-03-01 | Blume-Jensen Peter President and CEO | Grant or award · Stock Option (Right to Buy) | +417,210 | 417,210 | ||
| 2026-03-01 | Blume-Jensen Peter President and CEO | Grant or award · Stock Option (Right to Buy) | +185,495 | 185,495 | ||
| 2026-02-21 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −14,265 | $1.53 | $22K | 2,080,204 |
| 2026-02-14 | Peterson Katharine Chief Accounting Officer | Shares withheld for taxes | −116 | $1.63 | $189 | 4,006 |
| 2026-02-14 | Miller Mary Chief Legal Officer | Shares withheld for taxes | −217 | $1.63 | $354 | 33,679 |
| 2026-02-14 | Gamelin Erick Chief Development Officer | Shares withheld for taxes | −471 | $1.63 | $768 | 14,812 |
| 2026-02-14 | Devroe Eric Chief Operating Officer | Shares withheld for taxes | −723 | $1.63 | $1K | 74,585 |
| 2026-02-14 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −1,302 | $1.63 | $2K | 2,094,469 |
| 2026-02-14 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −579 | $1.63 | $944 | 314,127 |
| 2026-01-17 | Miller Mary Chief Legal Officer | Shares withheld for taxes | −659 | $1.98 | $1K | 33,896 |
Page 3 of 6 · 113 trades